Document Detail

Bromocriptine for induction of ovulation in hyperprolactinemic amenorrhea.
MedLine Citation:
PMID:  6475464     Owner:  NLM     Status:  MEDLINE    
Hyperprolactinemia is a frequent finding in infertile women with amenorrhea. Bromocriptine is the drug of choice for treatment of hyperprolactinemic amenorrhea. This dopamine agonist is very effective in normalizing raised prolactin levels. Ovulatory menstrual cycles and fertility are then rapidly restored. Bromocriptine therapy represents a major advance in the treatment of anovulatory infertility. Prolactin-secreting pituitary adenomas are common causes of hyperprolactinemia. Neither surgery nor irradiation reliably provides the definitive cure that had been hoped for in patients with prolactin-secreting pituitary tumours. Experience with medical treatment has revealed that induction of ovulation with bromocriptine is remarkably safe both in patients with microtumours and those with macrotumours without suprasellar extension. In the future, it is possible that even the larger macrotumours with suprasellar can be safely managed by medical therapy with bromocriptine. During pregnancy, pituitary tumour complications may arise in women with prolactinomas. However, data accumulated during recent years have shown that induction of ovulation and pregnancy by bromocriptine is remarkably safe in women with both micro- and macroprolactinomas. The risk of permanent sequelae due to rapid tumour enlargement during pregnancy is exceedingly small in properly investigated and carefully supervised women with prolactinomas. Bromocriptine is clearly a must for every infertility clinic. The value of bromocriptine in the treatment of normoprolactinemic amenorrhea, polycystic ovarian disease, luteal insufficiency and ovulatory infertility is not yet proven. However, bromocriptine is extremely effective in normalizing hyperprolactinemia and undoubtedly the drug of choice for treatment of female infertility due to hypersecretion of prolactin.
S J Nillius
Related Documents :
7383464 - Prenatal diagnosis of congenital adrenal hyperplasia.
12602544 - Prl-secreting pituitary adenomas in pregnancy.
20080854 - Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxyla...
8067644 - Visual loss in pregnant women with pituitary adenomas.
16885714 - Pharmacokinetics and pharmacotherapy of thionamides in pregnancy.
10927044 - New look at endometrial echogenicity: objective computer-assisted measurements predict ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta Europaea fertilitatis     Volume:  15     ISSN:  0587-2421     ISO Abbreviation:  Acta Eur. Fertil.     Publication Date:    1984 Mar-Apr
Date Detail:
Created Date:  1984-10-17     Completed Date:  1984-10-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1300660     Medline TA:  Acta Eur Fertil     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  83-91     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma / drug therapy,  secretion
Amenorrhea / blood,  drug therapy*
Bromocriptine / therapeutic use*
Diagnosis, Differential
Infertility, Female / blood,  drug therapy
Ovulation / drug effects*
Pituitary Neoplasms / drug therapy,  secretion
Pregnancy Complications / blood,  drug therapy
Prolactin / blood*
Reg. No./Substance:
25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Catecholamine levels in relation to number of spermatozoa inseminated "in vitro" in the human being.
Next Document:  Regional liver circulation and the scintigraphic representation of the portal circulation with 133Xe